Manual-guided psychosocial treatment: A new virtual requirement for pharmacotherapy trials?

Archives of General Psychiatry

Volumn 54, Issue 10, 1997, Pages 923-928

  Carroll, Kathleen M ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Substance Abuse Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

DRUG RESEARCH; HUMAN; MEDICAL ETHICS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS;

EID: 0031452403     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830220041007     Document Type: Review

References (81)

1. Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol. 1993;61:317-326.
2. Conte HR, Plutchik R, Wild KV, Karasu TB. Combined psychotherapy and pharmacotnerapy for depression: a systematic analysis of the evidence. Arch Gen Psychiatry. 1986;43:471-479.
3. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydierd B, Rasmussen S, White K, Sikes C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatient with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.
4. Mitchell JE, Raymond N, Specker S. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord. 1993;14:229-247.
5. Reynolds CF, Frank E, Perel JM, Imber SD, Cernes C, Morycz RK, Mazumdar S, Miller MD, Pollock BG, Rifai AN. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry. 1992;149:1687-1692.
6. Stack JA, Paradis CF, Reynolds CF, Houck PR, Frank E, Anderson B, Mayo AL, Miller MD, Rifai AH, Perel JM. Does recruitment method make a difference? effects on protocol retention and treatment outcome in elderly depressed patients. Psychiatry Res. 1995;56:17-24.
7. Callahan EJ. The treatment of heroin addiction: naltrexone alone with behavior therapy. Am J Drug Alcohol Abuse. 1980;7:795-807.
8. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848.
9. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119.
10. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E. A doubleblind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCI for alcohol dependence. Alcohol Clin Exp Res. 1994;18:1162-1167.
11. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979:chap1.
12. Kelly GR, Scott JE. Medication compliance and health education among outpatients with chronic mental disorders. Med Care. 1990;28:1181-1197.
13. Kupfer DJ, Perel JM, Frank E. Adequate treatment with imipramine in continuation treatment J Clin Psychiatry. 1989;50:250-255.
14. Meterissian GB, Bradwejn J. Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided? J Clin Psychopharmacol. 1989;9:334-339.
15. Ballenger J, Burrows G, Dupont R, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP. Alprazolam in agoraphobia with panic attacks and panic disorder: results from a murticenter trial. Arch Gen Psychiatry. 1988;45:413-422.
16. Kane JM, Borenstein M. Compliance in the longterm treatment of schizophrenia. PsychopharmaCol Bull. 1985;21:23-27.
17. Gelenberg A, Kane J, Keller M, Lavori P, Rosenbaum JF, Cole K, Lavelle J. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:1489-1493.
18. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I. Disulfiram treatment for alcoholism: a Veterans Administration cooperative Study. JAMA. 1986;256:1449-1455.
19. Frank E, Kupfer DJ, Siegel LR. Alliance not compliance: a philosophy of outpatient care. J Clin Psychiatry. 1995;56(suppl 1):11-16.
20. Feinstein AR. 'Compliance bias' and the interpretation of therapeutic trials. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979:309-322.
21. Lackin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to followup, noncompliance, and stratification. Biometrics. 1986;42:507-519.
22. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and non-compliance. Control Clin Trials. 1986;7:189-199.
23. Freedman LS. The effect of partial noncompliance on the power of a clinical trial. Control Clin Trials. 1990;11:157-168.
24. Pledger GW. Compliance in clinical trials: impact on design, analysis, and interpretation. In: Schmidt D, Leppick IE, eds. Compliance in Epilepsy, Amsterdam, the Netherlands: Elsevier Science Publishers; 1988.
25. Goldsmith CH. The effect of compliance distributions on therapeutic trials. In: Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979:297-308.
26. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6:39-48.
27. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? StetMed. 1991;10:1595-1605.
28. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol. 1992;21:837-841.
29. Nich C, Carroll KM. Now you see it, now you don't: a comparison of traditional versus random regression models in the analysis of longitudinal follow-up data from a clinical trial. J Consult Clin PsyChol. 1997;65:252-261.
30. Kraemer HC, Pruyn JP, Gibbons RD, Greenhouse JB, Grochinski VJ, Waternaux C, Kupfer DJ. Methodology in psychiatric research: report on the 1986 MacArthur Foundation Network I Methodology Instititute. Arch Gen Psychiatry. 1987;44:1100-1106.
31. Rabeneck L, Viscoli CM, Horwitz RI. Problems in the conduct and analysis of randomized clinical trials: are we getting the right answers to the wrong questions? Arch Intern Med. 1992;152:507-512.
32. Lang JM. The use of a run-in to enhance compliance. Stat Med. 1990;9:87-95.
33. Hennekens CH, Buring JE. Methodologic considerations in the design and conduct of randomized trials: the U.S. Physicians' Health Study, Control Clin Trials. 1989;10:142S-150S.
34. Epstein LH, Cluss PA. A behavioral medicine perspective on adherence to long-term medical regimens. J Consult Clin Psychol. 1982;50:950-971.
35. Howard K, Rickels K, Mock JE, Lipman RS, Covi L, Baumm NC. Therapeutic syle and attrition rate from psychiatric drug treatment. J Nerv Ment Dis. 1970;150:102-110.
36. Klerman GL. Assessing the influence of the hosptial milieu upon the effectiveness of psychiatric drug therapy: problems of conceptualization and of research methodology. J Nerv Ment Dis. 1963;137:143-154.
37. Uhlenhuth EH, Lipman RS, Covi L. Combined pharmacotherapy and psychotherapy: controlled studies. J Nerv Ment Dis. 1969;148:52-64.
38. Elkin I, Pilkonis PA, Docherty JP, Sotsky SM. Conceptual and methodological issues in comparative studies of psychotherapy and pharmacotherapy, I. active ingredients and mechanisms of change. Am J Psychiatry. 1988;145:909-917.
39. Klein DF. Improvement of phase III psychotropic drug trials by intensive phase II work, Neuropsychopharmacology. 1991;5:251-258.
40. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag NY Inc; 1991.
41. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953-1959.
42. Katon W, Von Korff MV, Lin E, Walker E, Simon GE, Bush T, Robinson P, Russe J. Collaborative managment to achieve treatment guidelines: impact on depression in primary care. JAMA. 1995;273:1026-1031.
43. DiMatteo RM, DiNicola DD. Achieving Patient Compliance. Elmsford, NY: Pergamon Press Inc; 1982.
44. Haynes RB, Taylor DW, Sackett DL, eds. Compliance in Health Care. Baltimore, Md: Johns Hopkins University Press; 1979.
45. Meichenbaum D, Turk DC, eds. Facilitating Treatment Adherence. New York, NY: Plenum Publishing Corp; 1987.
46. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med. 1993;153:1863-1868.
47. Fawcett J, Clark DC, Aagesen CA, Pisani VD, Tilkin JM, Sellers D, McGuire M, Gibbens RD. A double-blind, placebo-controlled trial of lithium carbonate therapy for alcoholism. Arch Gen Psychiatry. 1987;44:248-256.
48. Waskow IE. Specification of the technique variable in the NIMH Treatment of Depression Collaborative Research Program. In: Williams JBW, Spitzer RL, eds. Psychotherapy Research: Where Are We and Where Should We Go?New York, NY: Guilford Press; 1984.
49. Meyer RE, Mirin SM, Altman JL, McNamee HB. A behavioral paradigm for the evaluation of narcotic antagonists. Arch Gen Psychiatry. 1976;33:371-377.
50. Lambert MJ, Bergin AE. The effectiveness of psychotherapy. In: Bergin AE, Garfield SL, eds. Handbook of Psychotherapy and Behavior Change. 4th ed. New York, NY: John Wiley & Sons Inc; 1994: chap 7.
51. Horvath AO, Luborsky L. The role of the therapeutic alliance in psychotherapy. J Consult Clin Psychol. 1993;61:561-573.
52. Luborsky L, McLellan AT, Woody GE, O'Brien CP, Auerbach A. Therapist success and its determinants. Arch Gen Psychiatry. 1985;42:602-611.
53. Conen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates Inc; 1988.
54. Crits-Christoph P, Baranackie K, Kurcias J, Beck AT, Carroll K, Perry K, Luborsky L, McLellan AT, Woody GE, Thompson L, Gallagher D, Zitrin C. Meta-analysis of therapist effects in psychotherapy outcome studies. Psychother Res. 1991;1:81-91.
55. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
56. Schafer A. The ethics of the randomized clinical trial. N Engl J Med. 1982;307:719-724.
57. Levine RJ. The use of placebos in randomized clinical trials. IRB Rev Hum Subst Res. 1985;7:1-4.
58. Rothman KJ, Michels KB. The continued unethical use of placebo controls. N Engl J Med. 1994;331:394-398.
59. Kraemer HC, Pruyn JP. The evaluation of different approaches to randomized clinical trials: report on the 1987 MacArthur Foundation Network I Methodology Workshop. Arch Gen Psychiatry. 1990;47:1163-1169.
60. Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of cocaine addiction. J Clin Psychopharmacol. 1991;11:374-378.
61. Meyer RE. New pharmacotherapies for cocaine dependence. . . revisited. Arch Gen Psychiatry. 1992;49:900-904.
62. Williams JBW, Spitzer RL, eds. Psychotherapy Research: Where Are We and Where Should We Go? New York, NY: Guifford Press; 1984.
63. Luborsky L, DeRubeis RJ. The use of psychotherapy treatment manuals: a small revolution in psychotherapy research style. Clin Psychol Rev. 1984;4:5-15.
64. Kazdin AE. Methods of psychotherapy research. In: Bongar B, Beutler LE, eds. Comprehensive Text-book of Psychotherapy: Theoy and Practice. New York, NY: Oxford University Press Inc; 1995: chap 11.
65. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PD, Leber WR, Docherty JP, Rester SJ, Parioff MD. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry. 1989;46:971-982.
66. Hill CE, O'Grady KE, Elkin I. Applying the Collaborative Study Psychotherapy Rating Scale to rate therapist adherence in cognitive-behavior therapy, interpersonal therapy, and clinical management. J Consult Clin Psychol. 1992;60:73-79.
67. Carroll KM, Kadden R, Donovan D, Zweben D, Rounsaville BJ. Implementing treatment and protecting the validity of the independent variable in treatment matching studies. J Stud Alcohol. 1994; suppl 12:149-155.
68. Carroll KM, Nuro K. Treatment manuals and treatment compliance. In: Carroll KM, ed. Facilitating Compliance in Alcohol Treatment. Rockville, Md: National Institute on Alcoholism and Alcohol Abuse. In press. National Institute on Alcoholism and Alcohol Abuse Project MATCH Monograph Series.
69. Chevron E, Rounsaville BJ. Evaluating the clinical skills of psychotherapists: a comparison of techniques. Arch Gen Psychiatry. 1983;40:1129-1132.
70. Rounsaville BJ, Chevron E, Weissman MM, Prusoff BA, Frank E. Training therapists to perform interpersonal psychotherapy in clinical trials. Compr Psychiatry. 1986;27:364-371.
71. Weissman MM, Rounsaville BJ, Chevron E. Training psychotherapists to participate in psychotherapy outcome studies. Am J Psychiatry. 1982;139:1442-1446.
72. Elkin I, Parloff MB, Hadley SW, Autry JH. NIMH Treatment of Depression Collaborative Research Program: background and research plan. Arch Gen Psychiatry. 1985;42:305-316.
73. Waltz J, Addis ME, Koerner K, Jacobson NS. Testing the integrity of a psychotherapy protocol: assessment of adherence and competence. J Consult Clin Psychol. 1993;61:620-630.
74. DiClemente C, Carroll KM, Connors G, Kadden R. Process assessment in treatment matching research. J Stud Alcohol. 1994;12(suppl):156-162.
75. Carroll KM, Rounsaville BJ, Nich C. Use of observer and therapist ratings to monitor delivery of coping skills treatment for cocaine abusers: utility of therapist session checklists. Psychother Res. In press.
76. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
77. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal Psychotherapy of Depression. New York, NY: Basic Books Inc Publishers; 1984.
78. Luborsky L. Principles of Psychoanalytic Psychotherapy: A Manual for Supportive-Expressive (SE) Treatment. New York, NY: Basic Books Inc Publishers; 1984.
79. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management-imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 1987;23:309-324.
80. Klerman GL, Weissman MM, Markowitz J, Glick I, Wilner PJ, Mason B, Shear MK. Medication and psychotherapy 1&2. In: Bergin AE, Garfield SL, eds. Handbook of Psychotherapy and Behavior Change. 4th ed. New York, NY: John Wiley & Sons Inc; 1994.
81. Rounsaville BJ, Klerman GL, Weissman MM. Do psychotherapy and pharmacotherapy for depression conflict? empirical evidence from a clinical trial. Arch Gen Psychiatry. 1981;38:24-29.